Literature DB >> 33571146

Clonal dispersion of Acinetobacter baumannii in an intensive care unit designed to patients COVID-19.

Emilio Mariano Durán-Manuel1, Clemente Cruz-Cruz1, Gabriela Ibáñez-Cervantes1, Juan Carlos Bravata-Alcantará1, Oscar Sosa-Hernández2, Laura Delgado-Balbuena1, Gregorio León-García3, Iliana Alejandra Cortés-Ortíz1, Monica Alethia Cureño-Díaz1, Graciela Castro-Escarpulli4, Juan Manuel Vélez-Reséndiz3, Juan Manuel Bello-López5.   

Abstract

INTRODUCTION: SARS-CoV2 pandemic marks the need to pay attention to bacterial pathogens that can complicate the hospital stay of patients in the intensive care unit (ICU). ESKAPE bacteria which includes Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae are considered the most important, because of their close relationship with the development of ventilator-associated pneumonia (VAP). The aim of this work was to identify and characterize ESKAPE bacteria and to detect their possible clonal spread in medical devices, patients, and medical personnel of the ICU for COVID-19 patients of the Hospital Juarez de Mexico.
METHODOLOGY: Genetic identification of ESKAPE bacteria was performed by analyzing the 16S rRNA gene. Resistance assays were performed according to the CLSI guidelines. Assembly of AdeABCRS operon and inhibition assays of pumps efflux in Acinetobacter baumannii isolates were performed. Associated gene involved in biofilm formation (icaA) was performed in isolates belonging to the Staphylococcus genus. Finally, typing by ERIC-PCR and characterization of mobile genetic element SCCmec were done.
RESULTS: Heterogeneous distribution of ESKAPE and non-ESKAPE bacteria was detected in various medical devices, patients, and medical personnel. Acinetobacter baumannii and Staphylococcus aureus were the predominant ESKAPE members. The analysis of intergenic regions revealed an important clonal distribution of A. baumannii (AdeABCRS+). Genotyping of SCCmec mobile genetic elements and the icaA gene showed that there is no clonal distribution of S. aureus.
CONCLUSIONS: Clonal spread of A. baumannii (AdeABCRS+) highlights the importance of adopting good practices for equipment disinfection, surfaces and management of COVID-19 patients. Copyright (c) 2021 Emilio Mariano Duran-Manuel, Clemente Cruz-Cruz, Gabriela Ibanez-Cervantes, Juan Carlos Bravata-Alcantara, Oscar Sosa-Hernandez, Laura Delgado-Balbuena, Gregorio Leon-Garcia, Iliana Alejandra Cortes-Ortiz, Monica Alethia Cureno-Diaz, Graciela Castro-Escarpulli, Juan Manuel Velez-Resendiz, Juan Manuel Bello-Lopez.

Entities:  

Keywords:  Acinetobacter baumannii; COVID-19; ESKAPE; bacteria; clonal dispersion; intensive care unit

Year:  2021        PMID: 33571146     DOI: 10.3855/jidc.13545

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  8 in total

1.  Bacterial Resistance to Antibiotics and Clonal Spread in COVID-19-Positive Patients on a Tertiary Hospital Intensive Care Unit, Czech Republic.

Authors:  Lenka Doubravská; Miroslava Htoutou Sedláková; Kateřina Fišerová; Vendula Pudová; Karel Urbánek; Jana Petrželová; Magdalena Röderová; Kateřina Langová; Kristýna Mezerová; Pavla Kučová; Karel Axmann; Milan Kolář
Journal:  Antibiotics (Basel)       Date:  2022-06-08

Review 2.  Impact of SARS-CoV-2 Epidemic on Antimicrobial Resistance: A Literature Review.

Authors:  Francesco Vladimiro Segala; Davide Fiore Bavaro; Francesco Di Gennaro; Federica Salvati; Claudia Marotta; Annalisa Saracino; Rita Murri; Massimo Fantoni
Journal:  Viruses       Date:  2021-10-20       Impact factor: 5.048

3.  Structure of ATP synthase from ESKAPE pathogen Acinetobacter baumannii.

Authors:  Julius K Demmer; Ben P Phillips; O Lisa Uhrig; Alain Filloux; Luke P Allsopp; Maike Bublitz; Thomas Meier
Journal:  Sci Adv       Date:  2022-02-16       Impact factor: 14.136

4.  The impact of COVID-19 pandemic on nosocomial multidrug-resistant bacterial bloodstream infections and antibiotic consumption in a tertiary care hospital.

Authors:  Gökhan Metan; Mervenur Demir Çuha; Gülsen Hazirolan; Gülçin Telli Dizman; Elif Seren Tanriverdi; Baris Otlu; Zahit Tas; Pinar Zarakolu; Zafer Arik; Arzu Topeli; Seda Banu Akinci; Serhat Ünal; Ömrüm Uzun
Journal:  GMS Hyg Infect Control       Date:  2022-08-29

5.  The Burden of Carbapenem-Resistant Acinetobacter baumannii in ICU COVID-19 Patients: A Regional Experience.

Authors:  Giorgia Montrucchio; Silvia Corcione; Tommaso Lupia; Nour Shbaklo; Carlo Olivieri; Miriam Poggioli; Aline Pagni; Davide Colombo; Agostino Roasio; Stefano Bosso; Fabrizio Racca; Valeria Bonato; Francesco Della Corte; Stefania Guido; Andrea Della Selva; Enrico Ravera; Nicoletta Barzaghi; Martina Cerrano; Pietro Caironi; Giacomo Berta; Cecilia Casalini; Bruno Scapino; Michele Grio; Massimiliano Parlanti Garbero; Gabriella Buono; Federico Finessi; Simona Erbetta; Paola Federica Sciacca; Gilberto Fiore; Alessandro Cerutti; Sergio Livigni; Daniela Silengo; Fulvio Agostini; Maurizio Berardino; Mauro Navarra; Silvia Vendramin; Enzo Castenetto; Marco Maria Liccardi; Emilpaolo Manno; Luca Brazzi; Francesco Giuseppe De Rosa
Journal:  J Clin Med       Date:  2022-09-02       Impact factor: 4.964

6.  Whole-cell vaccine candidates induce a protective response against virulent Acinetobacter baumannii.

Authors:  Stephen J Dollery; Daniel V Zurawski; Ruth V Bushnell; John K Tobin; Taralyn J Wiggins; David A MacLeod; Naomi J P E R Tasker; Yonas A Alamneh; Rania Abu-Taleb; Christine M Czintos; Wanwen Su; Mariel G Escatte; Heather N Meeks; Michael J Daly; Gregory J Tobin
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

Review 7.  Acinetobacter baumannii Antibiotic Resistance Mechanisms.

Authors:  Ioannis Kyriakidis; Eleni Vasileiou; Zoi Dorothea Pana; Athanasios Tragiannidis
Journal:  Pathogens       Date:  2021-03-19

Review 8.  Review on Multiple Facets of Drug Resistance: A Rising Challenge in the 21st Century.

Authors:  Mousumi Saha; Agniswar Sarkar
Journal:  J Xenobiot       Date:  2021-12-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.